Hormone Replacement Therapy Beyond 5 Years Post-Menopause

Introduction to HRT Risks and Benefits

The American College of Cardiology recommends against oral estrogen-containing HRT in women ≥60 years or >10 years after menopause due to excess stroke risk 1
Initiating HRT more than 5 years after the last menstrual period is not recommended due to an unfavorable risk-benefit profile, with increased cardiovascular events, stroke, and thromboembolism that outweigh potential benefits 1, 2

Women under 60 years old OR within 10 years of menopause onset have the most favorable benefit-risk profile 1, 2
Women over 60 years old OR more than 10 years past menopause face excess cardiovascular and stroke risk that exceeds benefits 1, 2

For every 10,000 women taking estrogen-progestin for 1 year beyond the favorable window, there are 7 additional CHD events 1
For every 10,000 women taking estrogen-progestin for 1 year beyond the favorable window, there are 8 more strokes 1
For every 10,000 women taking estrogen-progestin for 1 year beyond the favorable window, there are 8 more pulmonary emboli 1
For every 10,000 women taking estrogen-progestin for 1 year beyond the favorable window, there are 8 more invasive breast cancers 1

The U.S. Preventive Services Task Force gives a Grade D recommendation (recommend against) for routine HRT use for chronic disease prevention in postmenopausal women 2
The American College of Obstetricians and Gynecologists and North American Menopause Society both recommend against HRT for cardiovascular or osteoporosis prevention, and advise caution about prolonged use even for symptoms 4

The only acceptable indication at this timepoint is severe, persistent vasomotor symptoms that significantly impair quality of life 1
Absolute contraindications to HRT include history of breast cancer or hormone-sensitive malignancies, active or history of venous thromboembolism or stroke, coronary heart disease or prior MI, active liver disease, antiphospholipid syndrome or positive antiphospholipid antibodies, and unexplained abnormal vaginal bleeding 1, 2

For osteoporosis prevention, consider bisphosphonates, denosumab, or selective estrogen receptor modulators (SERMs) rather than HRT 2
For vasomotor symptoms, non-hormonal options include SSRIs, gabapentin, and lifestyle modifications 2
For genitourinary symptoms, low-dose vaginal estrogen or non-hormonal vaginal moisturizers provide local benefit with minimal systemic absorption 1, 2

If asymptomatic or seeking HRT for prevention only, do not initiate HRT 3, 1, 2
If severe vasomotor symptoms persist, verify no absolute contraindications, trial non-hormonal options first, and use transdermal estradiol at lowest dose + appropriate progestin (if uterus intact) 1, 2